文献速递胸部肿瘤

替莫唑胺联合维利帕尼对比安慰剂治疗复发小细胞肺癌的随机双盲II期研究

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2018-06-15

本研究为随机双盲II期试验,104例复发小细胞肺癌患者按1:1随机接受替莫唑胺联合维利帕尼或安慰剂治疗,主要终点为4个月无进展生存率。

要点

  • 联合维利帕尼未显著改善4个月PFS率与中位OS
  • SLFN11阳性者联合治疗PFS与OS显著延长

核心结论

  • 替莫唑胺联合维利帕尼未改善4个月PFS与中位OS,但显著提高ORR,SLFN11表达可能提示PARP抑制剂敏感性。

研究设计与样本

  • 随机双盲II期研究,共104例复发小细胞肺癌患者按1:1随机分组。
  • 维利帕尼或安慰剂40 mg每日两次口服,第1至7天;替莫唑胺150至200 mg/m2/日口服,第1至5天,28天为一周期。
  • 主要终点为4个月无进展生存改善,次要终点包括ORR、OS及安全性与耐受性。
  • 探索性终点包括PARP-1与SLFN11免疫组化表达、MGMT启动子甲基化及循环肿瘤细胞定量。

主要发现

  • 3/4级血小板减少:替莫唑胺/维利帕尼组50% vs 安慰剂组9%;3/4级中性粒细胞减少:31% vs 7%。

临床怎么用

  • 替莫唑胺联合维利帕尼不宜仅以PFS或OS获益为目的用于复发小细胞肺癌。
  • 联合方案可提高客观缓解率,但需权衡3/4级血液学毒性明显增加。
  • SLFN11表达检测可能有助于筛选PARP抑制剂联合治疗的潜在获益人群。

局限性

  • 为II期研究,样本量104例,结论需更大规模研究验证。
  • SLFN11等生物标志物分析属探索性目的,尚未确立为常规筛选标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m2/day, days 1 to 5, of a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent. Response was determined by imaging at weeks 4 and 8, and every 8 weeks thereafter. Improvement in PFS at 4 months was the primary end point. Secondary objectives included overall response rate (ORR), overall survival (OS), and safety and tolerability of veliparib with TMZ. Exploratory objectives included PARP-1 and SLFN11 immunohistochemical expression, MGMT promoter methylation, and circulating tumor cell quantification. Results No significant difference in 4-month PFS was noted between TMZ/veliparib (36%) and TMZ/placebo (27%; P = .19); median OS was also not improved significantly with TMZ/veliparib (8.2 months; 95% CI, 6.4 to 12.2 months; v 7.0 months; 95% CI, 5.3 to 9.5 months; P = .50). However, ORR was significantly higher in patients receiving TMZ/veliparib compared with TMZ/placebo (39% v 14%; P = .016). Grade 3/4 thrombocytopenia and neutropenia more commonly occurred with TMZ/veliparib: 50% versus 9% and 31% versus 7%, respectively. Significantly prolonged PFS (5.7 v 3.6 months; P = .009) and OS (12.2 v 7.5 months; P = .014) were observed in patients with SLFN11-positive tumors treated with TMZ/veliparib. Conclusion Four-month PFS and median OS did not differ between the two arms, whereas a significant improvement in ORR was observed with TMZ/veliparib. SLFN11 expression was associated with improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of PARP-inhibitor sensitivity in SCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pietanza MC, Waqar SN, Krug LM, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29906251. doi:10.1200/JCO.2018.77.7672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。